The objective of this study is to determine whether oral NAC is effective at attenuating COVID-19 disease symptom severity and duration of symptoms.
STUDY DESIGN: Randomized double-blinded placebo-controlled trial ELIGIBILITY Inclusion criteria: * age 18 years and older * participants will need daily access to use of a smartphone for at least six weeks from time of enrollment * Positive COVID-19 test within 10 days of date of enrollment * not already hospitalized for treatment of COVID Exclusion criteria: * pregnant * already hospitalized for treatment of COVID PROTOCOL * 50:50 randomization: half of participants will take NAC, half will take placebo * Participants will take NAC/placebo following this outpatient protocol: * 2400 mg x 1 PO then * 1200 mg PO BID x 14 days * Participants will complete an online symptom-tracker for six weeks (daily for three weeks, weekly for three weeks)
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
200
N-acetylcysteine
Placebo
Cambridge Health Alliance
Everett, Massachusetts, United States
Symptom severity
Severity of symptoms
Time frame: 24 weeks starting the day after enrollment
Symptom duration
Length in days of symptoms
Time frame: 24 weeks starting the day after enrollment
Need for higher level of care/hospitalization
Comparison between groups of rates of hospitalization
Time frame: 24 weeks starting the day after enrollment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.